Why Is NEUROCRINE BIOSCIENC (NBIX) Stock Moving Today?

Neurocrine Biosciences (NBIX) stock is moving lower today, down 0.34 percent to $166.23 as of the latest trade. The stock has faced downward pressure amid recent insider selling and a broader price trend of -3.4 percent over the last eight sessions. Despite recent analyst upgrades and strong second-quarter revenue results, the stock has struggled to maintain momentum.

What Happened

Neurocrine reported second-quarter 2026 revenue of $950 million, with INGREZZA sales rising 15 percent and CRENESSITY sales growing 20 percent. These results were highlighted in a Motley Fool transcript of the earnings call. Analysts at H.C. Wainwright and Canaccord have reiterated or upgraded their ratings for the stock, citing progress in the company’s pipeline and strong sales performance. Canaccord raised its price target to $210, while other firms including Truist, Wedbush, and RBC also raised their price targets. Despite these positive signals, the stock has seen a decline in recent trading.

What The Data Shows

Over the past eight trading sessions, the stock has fallen from $172.69 to $166.80, reflecting a broader bearish trend. Insider transactions have also been notable, with 15 sales reported in the last 90 days totaling $62.4 million. The most recent sale was reported on July 30. The stock is currently trading within its 52-week range of $122.14 to $186.12, with a market cap of $17.0 billion and a P/E ratio of 24.4. Revenue has grown 34.4 percent in the trailing twelve months, and the company maintains a net margin of 20.9 percent.

What To Watch

The stock is currently trading below recent analyst price targets, which range from $194 to $249. Coverage breadth remains strong, with multiple analysts maintaining positive ratings. Investors may look for further analyst commentary or potential earnings surprises in the coming months.